Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations

Lung Cancer. 2019 Oct:136:153-155. doi: 10.1016/j.lungcan.2019.07.030. Epub 2019 Jul 31.

Authors

Wei Heng¹, Chuanyun You², Cai Shangli³, Qi Chuang³, Xiao Mingzhe³

Affiliations

¹ The Department of respiratory medicine, the First Affiliated Hospital of Soochow University, China. Electronic address: hengwei002@126.com.
² The Department of respiratory medicine, the First Affiliated Hospital of Soochow University, China.
³ The Medical Department, 3D Medicines Inc., Shanghai, China.

PMID: 31422893
DOI: 10.1016/j.lungcan.2019.07.030

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma of Lung / diagnosis
Adenocarcinoma of Lung / drug therapy
Adenocarcinoma of Lung / genetics*
Aged
Amino Acid Substitution
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Crown Ethers / pharmacology*
Crown Ethers / therapeutic use
Drug Resistance, Neoplasm / genetics*
ErbB Receptors / chemistry
ErbB Receptors / genetics
Female
Humans
Lung Neoplasms / diagnosis
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Mutation*
Quinazolines / pharmacology*
Quinazolines / therapeutic use
Structure-Activity Relationship
Treatment Outcome

Substances

Antineoplastic Agents
Crown Ethers
Quinazolines
icotinib
EGFR protein, human
ErbB Receptors